D rip-and-ship acute ischemic stroke treatment paradigm has been evaluated in multiple single centers and regional studies. 1, 2, 3 The paradigm consists of initiating intravenous recombinant tissue-type plasminogen activator (rt-PA) infusion at smaller community and rural hospitals and then transporting patients to established stroke centers within 24 hours for postthrombolytic care. A population-based study ascertaining the utilization and impact of a drip-and-ship paradigm that reflects the heterogeneity of implementation by various practices and is derived from various racial/ethnic and socioeconomic population groups is not available. 4 Discharge destinations were divided into home discharge/self-care (favorable outcome), home health care, short-term care facility (including inpatient rehabilitation), long-term nursing facility, and in-hospital death. Thrombolytic utilization per state and patterns of referral (final destination of urban teaching hospital) were determined in patients treated using the drip-and-ship paradigm. SAS 9.1 software (SAS Institute, Inc) was used to provide weighted national estimates. Logistic regression analysis was used to examine the impact of drip-and-ship paradigm on clinical outcome of patients after adjusting for potential confounders.
Results
The overall utilization rate of thrombolytic treatment was 4.3% among 623 958 acute ischemic stroke patients admitted during the 14-month period. Of 22 243 patients who received thrombolytic treatment, 4474 patients (17%) were treated using the drip-and-ship paradigm. Of these 4474 patients, 81% were referred to urban teaching hospitals for additional care, and 7% of them received follow-up endovascular treatment. The rates of thrombolytic treatment for primary emergency department arrival and drip-and-ship paradigm within the United States ranged from 1.07% to 7.13%, and 0% to 3.69%, respectively. States in the upper quartile for high drip-and-ship utilization had higher rates of thrombolytic utilization compared with those in the lower quartile (5.4% versus 3.3%; PϽ0.001; Figure) . Patients treated with drip-and-ship paradigm were more likely to be admitted to teaching hospitals (81.5% versus 61.1%; PϽ0.0001). Drip-and-ship paradigm was associated with shorter hospital stay (mean [ Table  1 ). After adjusting for age, sex, presence of hypertension, diabetes mellitus, renal failure, congestive heart failure, and hospital teaching status, the rate of home discharge/self-care was significantly higher in patients treated with the drip-and-ship paradigm compared with those who received thrombolytics through primary emergency department arrival in the multivariate analysis (OR, 1.198; 95% CI, 1.019 -1.409; Pϭ0.0286; Table 2 ).
Discussion
Drip-and-ship paradigm was used in 17% of all patients treated with intravenous rt-PA for acute ischemic stroke, and 81% of those were transferred to an urban teaching hospital. There was variability in rates of utilization among states, [5] [6] [7] [8] and states with the highest proportion of drip-and-ship cases were also the states with the highest overall thrombolytic utilization ( Figure 1 ). Whether this association reflects a cause-and-effect relationship or merely a marker of more developed stroke systems needs to be studied. The overall impact of the drip-and-ship paradigm may appear modest, as it was only utilized in 17% of all rt-PA-treated stroke patients.
We observed that patients treated with the drip-and-ship paradigm had significantly higher rates of home discharge/ self-care compared with patients treated with intravenous rt-PA through primary emergency department arrival. Whereas baseline stroke severity measures (eg, admission National Institutes of Health Stroke Scale) for adjusted comparison are not available, lower rates of hospital complications (pneumonia and urinary tract infection), and mechanical ventilation (Table 1) suggest that drip-and-ship patients have a lower severity of deficits consistent with findings of Get With the Guidelines-Stroke analysis. 8 The exact interpretation of lower hospitalization charges associated with the drip-and-ship paradigm is also confounded by differences in patient characteristics and pharmacy cost of rt-PA.
Limitations
Although the sensitivity of V45.88 for ascertaining the use of drip-and-ship is high 9 in selected centers, the variation in sensitivity rates among numerous sites may impact and underestimate utilization rates.
One issue that we are unable to answer is the impact of the drip-and-ship paradigm on door-to-needle time, and whether reduction in transport time is offset by relatively slower response time within the emergency department of the referring facility.
Conclusions
Higher rates of implementation of the drip-and-ship paradigm were associated with higher rate of overall thrombolytic 
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utilization and final admission to urban teaching hospitals, supporting the role of this paradigm as an important strategy to improve the national rate and postadministration care of intravenous rt-PA utilization.
